https://orcid.org/0000-0001-5414-8148
References
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi:10.1001/jama.2020.1585
- Seki M. Trends in the management of infectious disease under SARS-CoV-2 era: from pathophysiological comparison of COVID-19 and influenza. World J Virol. 2021;10:62–68. doi:10.5501/wjv.v10.i2.62
- Bhimraj A, Morgan R, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa478
- Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. doi:10.1136/bmj.m3379
- Fernández-Cruz A, Puyuelo A, Núñez Martín-Buitrago L, et al. Higher mortality of hospitalized haematologic patients with COVID-19 compared to non-haematologic is driven by thrombotic complications and development of ARDS: an age-matched cohorts study. Clin Infect Pract. 2022;13:100137. doi:10.1016/j.clinpr.2022.100137
- Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168. doi:10.1186/s13045-021-01177-0
- Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139:1588–1592. doi:10.1182/blood.2021014124
- Salmanton-García J, Marchesi F, Glenthøj A, et al. Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of Anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere. 2022;6:e789. doi:10.1097/HS9.0000000000000789
- Infante MS, Salmanton-García J, Fernández-Cruz A, et al. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: a European hematology association survey (EPICOVIDEHA). Front Oncol. 2022;12:992137. doi:10.3389/fonc.2022.992137
- Kmeid J, Vanichanan J, Shah DP, et al. Outcomes of influenza infections in hematopoietic cell transplant recipients: application of an immunodeficiency scoring index. Biol Blood Marrow Transplant. 2016;22:542–548. doi:10.1016/j.bbmt.2015.11.015
- Sheshadri A, Chemaly R, Alousi AM, et al. Pulmonary impairment after respiratory viral infections is associated with high mortality in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2019;25:800–809. doi:10.1016/j.bbmt.2018.11.022
- Fox TA, Troy-Barnes E, Kirkwood AA, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol. 2020;191:194–206. doi:10.1111/bjh.17027
- Chamilos G, Lionakis M, Kontoyiannis DP. Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)? Clin Infect Dis. 2021;72:351–356. doi:10.1093/cid/ciaa1079
- García-Suárez J, de la Cruz J, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13:133. doi:10.1186/s13045-020-00970-7